Silencing of microRNAs in vivo with ‘antagomirs’ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10-30

AUTHORS

Jan Krützfeldt, Nikolaus Rajewsky, Ravi Braich, Kallanthottathil G. Rajeev, Thomas Tuschl, Muthiah Manoharan, Markus Stoffel

ABSTRACT

miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function — and a potential therapeutic strategy for silencing miRNAs in disease. These ‘antagomirs’ are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation. More... »

PAGES

685-689

Journal

TITLE

Nature

ISSUE

7068

VOLUME

438

Related Patents

  • Multimeric Oligonucleotides Compounds
  • 5′-End Derivatives
  • Gene Vector
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Mir-92 Inhibitors And Uses Thereof
  • Polycomb-Associated Non-Coding Rnas
  • Multimeric Oligonucleotides Compounds Having Cleavable Linkers
  • Methods For Regulating Neural Differentiation
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Mir-122* As An Active Micro-Rna, Compositions Comprising The Same And Uses Thereof
  • Method Of Inhibiting Mir-33 Using A Modified Oligonucleotide
  • Polycomb-Associated Non-Coding Rnas
  • Method For Promoting Angiogenesis, Vascularization Or Vessel Repair Or For Inhibiting Tumor Angiogenesis
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Esophageal Microrna Expression Profiles In Eosinophilic Esophagitis
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Modulation Of Innate Immunity Receptors' Signaling By Micrornas Mir-146a And Mir-146b
  • Using Modulator Of Tumor Necrosis Factor (Tnf) Pathway Such As Infliximab, Simvastatin; Drug Screening
  • Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications
  • Modified Antimir-138 Oligonucleotides
  • Mir-106a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Aav Treatment Of Huntington's Disease
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Micrornas In Neurodegenerative Disorders
  • Compositions And Methods For Modulating Utrn Expression
  • Antisense Microrna And Uses Therefor
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Raav-Based Compositions And Methods
  • Sequence-Specific Cellular Uptake Of Spherical Nucleic Acid Nanoparticle Conjugates
  • Double-Stranded Agents For Delivering Therapeutic Oligonucleotides
  • Compositions And Methods For Modulating Smn Gene Family Expression
  • Sirna And Their Use In Methods And Compositions For The Treatment And / Or Prevention Of Eye Conditions
  • Microrna Inhibitors
  • Reduced Size Self-Delivering Rnai Compounds
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Chiral Nucleic Acid Adjuvant
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Compositions And Methods For Modulating Atp2a2 Expression
  • Compositions And Methods For The Diagnosis And Treatment Of Bone Fractures And Disorders
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Chiral Nucleic Acid Adjuvant Having Anti-Allergic Activity, And Anti-Allergic Agent
  • Method For Treating Myocardial Infarct
  • Nucleic Acid Functionalized Nonoparticles For Therapeutic Applications
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • The Use Of Mirna Particles And Mirna Antagomir For Diagnostics, Prevention And Treatment Of Multiple Sclerosis
  • Oligonucleotides Useful For Detecting And Analyzing Nucleic Acids Of Interest
  • Supercharged Proteins For Cell Penetration
  • Gene Vector
  • Antisense Compounds Having Enhanced Anti-Microrna Activity
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Mir-21 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Recombinant Aavs Having Useful Transcytosis Properties
  • Nucleic Acid Prodrugs And Methods Of Use Thereof
  • Hybrid Oligonucleotides And Uses Thereof
  • Raav-Based Compositions And Methods For Treating Alpha-1 Anti-Trypsin Deficiencies
  • Methods And Compositions For Modulating Mir-204 Activity
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Inhibitors Of The Microrna Argonaute Protein Complex
  • Aav's And Uses Thereof
  • Protein Surface Remodeling
  • Micrornas
  • Administration Of Exogenous Mirna Or Sirna
  • Treatment Of Cns Conditions
  • Novel Micrornas For The Detection And Isolaton Of Human Embryonic Stem Cell-Derived Cardiac Cell Types
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Regulation Of Hematopoietic Stem Cell Functions Through Micrornas
  • Polycomb-Associated Non-Coding Rnas
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Nanoconjugates Able To Cross The Blood-Brain Barrier
  • Double-Stranded Agents For Delivering Therapeutic Oligonucleotides
  • Isolation Of Novel Aav's And Uses Thereof
  • Modified Aav Constructs And Uses Thereof
  • Regulation Of Epigenetic Control Of Gene Expression
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Cancer
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Blood-Brain Barrier Permeable Heteroduplex Nucleic Acid
  • The Mirna-212/132 Family As A Therapeutic Target
  • Microrna-Based Methods And Assays For Osteocarcinoma
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Heterologous Targeting Peptide Grafted Aavs
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Methods And Compositions For Detection Of Cowden Syndrome (Cs) And Cs-Like Syndrome
  • Templated Nanoconjugates
  • Combination Treatment For The Treatment Of Hepatitis C Virus Infection
  • Inhibition Of Microrna-134 For The Treatment Of Seizure-Related Disorders And Neurologic Injuries
  • Aav's And Uses Thereof
  • Mir-29a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Methods For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Polycomb-Associated Non-Coding Rnas
  • Microrna-Based Methods And Compositions For The Diagnosis, Prognosis And Treatment Of Tumor Involving Chromosomal Rearrangements
  • Raav-Based Compositions And Methods For Treating Alpha-1 Anti-Trypsin Deficiencies
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Oligonucleotide Conjugates
  • Delivery Of Oligonucleotide Functionalized Nanoparticles
  • Nanoconjugates Able To Cross The Blood-Brain Barrier
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Inhibition Of Microrna-134 For The Treatment Of Seizure-Related Disorders And Neurologic Injuries
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Heterologous Targeting Peptide Grafted Aavs
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Aav's And Uses Thereof
  • Methods For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Microrna Composition For The Treatment Of Neuroblastoma
  • Mir-29a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Compositions And Methods For Modulating Hemoglobin Gene Family Expression
  • Antisense Oligonucleotides For Inhibition Of Microrna-21
  • Polycomb-Associated Non-Coding Rnas
  • Oligonucleotide Conjugates
  • Combination Treatment For The Treatment Of Hepatitis C Virus Infection
  • Methods And Compositions For Detection Of Cowden Syndrome (Cs) And Cs-Like Syndrome
  • Templated Nanoconjugates
  • Administration Of Exogenous Mirna Or Sirna
  • Mir-203 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Medicament For The Treatment Of Cardiac Disease
  • Modulators Of Mir-323-3p For The Prevention Or Treatment Of Rheumatoid Arthritis
  • Sequence-Specific Inhibition Of Small Rna Function
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Uses And Compositions Comprising Mirnas
  • Micro-Rna Mediated Modulation Of Colony Stimulating Factors
  • Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell
  • Microrna Inhibitors Comprising Locked Nucleotides
  • Cns Targeting Aav Vectors And Methods Of Use Thereof
  • Chiral Control
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Chiral Design
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Targeting Glioma Stem Cells By Sequence-Specific Functional Inhibition Of Pro-Survival Oncomir-138
  • Chiral Nucleic Acid Adjuvant Having Immunity Induction Activity, And Immunity Induction Activator
  • Distinguishing Benign And Malignant Indeterminate Thyroid Lesions
  • Antisense Microrna And Uses Therefor
  • Anti-Mir-27b And Anti-Mir-148a Oligonucleotides As Therapeutic Tools For Treating Dyslipidemias And Cardiovascular Diseases
  • Adoptive Cell Therapy Using Spherical Nucleic Acids (Snas)
  • Raav-Based Compositions And Methods
  • Microrna Inhibitors
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Polycomb-Associated Non-Coding Rnas
  • Use Of Nucleic Acids With Reduced Pressure Therapy
  • Methods For The Synthesis Of Functionalized Nucleic Acids
  • Nanoconjugates Able To Cross The Blood-Brain Barrier
  • Compounds Of Chemically Modified Oligonucleotides And Methods Of Use Thereof
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Method For The Inhibition Of Angiogenesis
  • The Mirna-212/132 Family As A Therapeutic Target
  • Polyvalent Rna-Nanoparticle Compositions
  • Sirnas And Their Use In Methods And Compositions For The Treatment And/Or Prevention Of Eye Conditions
  • Recombinant Aavs Having Useful Transcytosis Properties
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Methods Employing Non-Coding Rna Expression Assays
  • Asymmetric Auxiliary Group
  • Protein Surface Remodeling
  • Antisense Rna For Treating Cancer And Inhibition Of Metastasis And Vectors For Antisense Sequestration
  • Methods For Inducing Cardiomyocyte Proliferation
  • Methods And Compositions For The Treatment Of Intestinal Conditions
  • Microrna (Mirna) And Down-Stream Targets For Diagnostic And Therapeutic Purposes
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Isolation Of Novel Aav's And Uses Thereof
  • Aav's And Uses Thereof
  • Magnetic Nanoparticle-Samirna Complex And Method For Preparing Same
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Cancer
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Micro-Rna's That Regulate Muscle Cells
  • Muc1 And Galectin-3
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Microrna Antisense Pnas, Compositions Comprising The Same, And Methods For Using And Evaluating The Same
  • Methods For Use In Modulating Mir-122a
  • Multimeric Oligonucleotide Compounds Having Non-Nucleotide Based Cleavable Linkers
  • The Mirna-212/132 Family As A Therapeutic Target
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Gene Vector
  • Light Inducible Antisense Oligonucleotides For In Vivo Application
  • Identification Of Novel Genes Coding For Small Temporal Rnas
  • Methods For Including Cardiomyocyte Proliferation
  • Methods And Compositions For The Detection And Treatment Of Cancer Involving Mirnas And Mirna Inhibitors And Targets
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Breast Cancer
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Protein Surface Remodeling
  • Isolation Of Novel Aav's And Uses Thereof
  • Micromirs
  • Isolation Of Novel Aav's And Uses Thereof
  • Methods For Regulating Neural Differentiation
  • Chiral Nucleic Acid Adjuvant Having Antitumor Effect And Antitumor Agent
  • Methods Of Delivering Multiple Targeting Oligonucleotides To A Cell Using Cleavable Linkers
  • Transcriptome-Wide Design Of Selective, Bioactive Small Molecules Targetting Rna
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Methods For Modulating Atrx-Dependent Gene Repression
  • Method For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Polycomb-Associated Non-Coding Rnas
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Methods For Modulating Atrx-Dependent Gene Repression
  • Method For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Microrna Antisense Pnas, Compositions Comprising The Same, And Methods For Using And Evaluating The Same
  • Multicistronic Expression Constructs
  • Transcriptome-Wide Design Of Selective, Bioactive Small Molecules Targetting Rna
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Microrna (Mirna) For The Diagnosis And Treatment Of Heart Diseases
  • Gene Vector
  • Modulation Of 11beta-Hydroxysteriod Dehydrogenase 1 Expression For The Treatment Of Ocular Diseases
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Compositions And Methods For Cancer Diagnosis And Treatment
  • Gene Vector
  • Micromirs
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • The Mirna-212/132 Family As A Therapeutic Target
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Methods And Compositions For The Detection And Treatment Of Cancer Involving Mirnas And Mirna Inhibitors And Targets
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Breast Cancer
  • Multimeric Oligonucleotide Compounds Having Non-Nucleotide Based Cleavable Linkers
  • Identification Of Novel Genes Coding For Small Temporal Rnas
  • Mir27b Is A Novel Target For Treatment Of Liver Fibrosis
  • Methods For Regulating Neural Differentiation
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Methods For Including Cardiomyocyte Proliferation
  • Light Inducible Antisense Oligonucleotides For In Vivo Application
  • Mir-92 Inhibitors And Uses Thereof
  • Chiral Auxiliaries
  • Polycomb-Associated Non-Coding Rnas
  • Chiral Nucleic Acid Adjuvant Having Antitumor Effect And Antitumor Agent
  • Microrna-Based Methods And Assays For Osteocarcinoma
  • Micromirs
  • Isolation Of Novel Aav's And Uses Thereof
  • Particles For Detecting Intracellular Targets
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Targeting Microrna-26a/B For The Treatment Of Neurodegenerative Disease
  • Antidote Oligomers
  • Polycomb-Associated Non-Coding Rnas
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Multimetric Oligonucleotide Compounds
  • Rna Interactome Of Polycomb Repressive Complex 1 (Prc1)
  • Crosslinked Micellar Spherical Nucleic Acids
  • Recombinant Aav Vectors Useful For Reducing Immunity Against Transgene Products
  • Antisense Rna For Treating Cancer And Inhibition Of Metastasis And Vectors For Antisense Sequestration
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Raav-Based Compositions And Methods
  • Asymmetric Auxiliary Group
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Oligonucleotide Conjugates
  • Isolation Of Novel Aav's And Uses Thereof
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Mir-10a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma
  • Recombinant Aav Variants And Uses Thereof
  • Multimeric Oligonucleotide Compounds
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Sequence-Specific Inhibition Of Small Rna Function
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Control Of Whole Body Energy Homeostasis By Microrna Regulation
  • Compositions And Methods For Modulating Mecp2 Expression
  • Inhibition Of Microrna-134 For The Treatment Of Seizure-Related Disorders And Neurologic Injuries
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Mir-103-2 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Methods And Compositions For The Treatment Of Intestinal Conditions
  • Cns Targeting Aav Vectors And Methods Of Use Thereof
  • Polyvalent Rna-Nanoparticle Compositions
  • Modulation Of Mirna In Diseases With Aberrant Angiogenesis
  • Microrna Antisense Pnas, Compositions Comprising The Same, And Methods For Using And Evaluating The Same
  • Methods For The Synthesis Of Functionalized Nucleic Acids
  • Aav's And Uses Thereof
  • Microrna Composition For The Treatment Of Neuroblastoma
  • Multicistronic Expression Constructs
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Micro-Rna's That Regulate Muscle Cells
  • Use Of Microrna-24 And/Or Its Targets For The Treatment And Prevention Of Ischemia And Induction Of Angiogenesis
  • Methods Employing Non-Coding Rna Expression Assays
  • Anti-Angiogenic Mirna Therapeutics For Inhibiting Corneal Neovascularization
  • Gene Vector
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Microrna-Based Methods And Compositions For Reprogramming Cells
  • Templated Nanoconjugates
  • Microrna For Diagnostic And Therapeutic Purposes In Cardiovascular Diseases
  • Pharmaceutical Compositions For Treatment Of Hcv Patients That Are Poor-Responders To Interferon
  • Therapeutic Targets And Molecules
  • Distinguishing Benign And Malignant Indeterminate Thyroid Lesions
  • Sequence-Specific Inhibition Of Small Rna Function
  • Nucleic Acid Prodrugs And Methods Of Use Thereof
  • Polycomb-Associated Non-Coding Rnas
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nature04303

    DOI

    http://dx.doi.org/10.1038/nature04303

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1045870087

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16258535


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0604", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Genetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "3' Untranslated Regions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antagomirs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholesterol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Computational Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Down-Regulation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Silencing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "MicroRNAs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA, Complementary", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sensitivity and Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Substrate Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Up-Regulation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kr\u00fctzfeldt", 
            "givenName": "Jan", 
            "id": "sg:person.01326501171.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326501171.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.137628.9", 
              "name": [
                "Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rajewsky", 
            "givenName": "Nikolaus", 
            "id": "sg:person.0604110653.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604110653.10"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Braich", 
            "givenName": "Ravi", 
            "id": "sg:person.0651210271.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651210271.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rajeev", 
            "givenName": "Kallanthottathil G.", 
            "id": "sg:person.01127665173.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127665173.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tuschl", 
            "givenName": "Thomas", 
            "id": "sg:person.010011672437.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010011672437.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manoharan", 
            "givenName": "Muthiah", 
            "id": "sg:person.0650611705.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650611705.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stoffel", 
            "givenName": "Markus", 
            "id": "sg:person.01211623670.71", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211623670.71"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.gt.3302654", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022653137", 
              "https://doi.org/10.1038/sj.gt.3302654"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03702", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024825726", 
              "https://doi.org/10.1038/nature03702"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03121", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043296399", 
              "https://doi.org/10.1038/nature03121"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrg1379", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001799892", 
              "https://doi.org/10.1038/nrg1379"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03552", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020637207", 
              "https://doi.org/10.1038/nature03552"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03315", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002085290", 
              "https://doi.org/10.1038/nature03315"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03817", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035771095", 
              "https://doi.org/10.1038/nature03817"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1536", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037192337", 
              "https://doi.org/10.1038/ng1536"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature02871", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043341870", 
              "https://doi.org/10.1038/nature02871"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03076", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050225907", 
              "https://doi.org/10.1038/nature03076"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-10-30", 
        "datePublishedReg": "2005-10-30", 
        "description": "miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function \u2014 and a potential therapeutic strategy for silencing miRNAs in disease. These \u2018antagomirs\u2019 are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nature04303", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7068", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "438"
          }
        ], 
        "keywords": [
          "gene regulation", 
          "non-coding RNA", 
          "examples of miRNAs", 
          "important developmental role", 
          "developmental genes", 
          "natural miRNAs", 
          "miRNA regulation", 
          "mammalian systems", 
          "transcription factors", 
          "developmental role", 
          "developmental processes", 
          "mouse embryos", 
          "biological processes", 
          "miRNAs", 
          "miRNA expression", 
          "potential therapeutic strategy", 
          "specific role", 
          "genes", 
          "microRNAs", 
          "regulation", 
          "embryos", 
          "miR-16", 
          "antagomir", 
          "expression", 
          "vertebrates", 
          "therapeutic strategies", 
          "vivo", 
          "powerful tool", 
          "bone marrow", 
          "HOXB8", 
          "RNA", 
          "flies", 
          "group of compounds", 
          "role", 
          "such example", 
          "sequence", 
          "mice", 
          "worms", 
          "oligonucleotide", 
          "function", 
          "discovery", 
          "marked reduction", 
          "ovaries", 
          "target", 
          "mechanism", 
          "marrow", 
          "intestine", 
          "muscle", 
          "process", 
          "levels", 
          "compounds", 
          "factors", 
          "liver", 
          "disease", 
          "acts", 
          "kidney", 
          "heart", 
          "strategies", 
          "tool", 
          "study", 
          "example", 
          "skin", 
          "reduction", 
          "adrenals", 
          "lung", 
          "accurate expression", 
          "fat", 
          "system", 
          "group", 
          "idea", 
          "administration", 
          "perception", 
          "secondary level", 
          "intravenous administration"
        ], 
        "name": "Silencing of microRNAs in vivo with \u2018antagomirs\u2019", 
        "pagination": "685-689", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1045870087"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nature04303"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16258535"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nature04303", 
          "https://app.dimensions.ai/details/publication/pub.1045870087"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:33", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_395.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nature04303"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nature04303'


     

    This table displays all metadata directly associated to this object as RDF triples.

    289 TRIPLES      21 PREDICATES      125 URIs      106 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nature04303 schema:about N18e178dc693841798b150d78fec22d57
    2 N1edaad83b596466cba2b2ea6f90d23bf
    3 N4fdf5a633bfb45d39f82a8cb84ef1ba7
    4 N619c8c5333ea4ffaa994d9a7ae09524f
    5 N7661ea684af44c93b40f20747dc86b66
    6 N8ed30c5c576d471e8ce6487cdb3480d8
    7 N964706bfd5884740a88fc015521b91b6
    8 Nb8ff85016fb9493785003831264faadf
    9 Nb95ecda74ff74ebca32da74673d7db94
    10 Nc67b059184894c4f940ce6b793b2fbc4
    11 Nd4f6df786a5e4d5d9f0ad854f980fa7c
    12 Ne36d941fae9747f3b0d6ba6fe57b47aa
    13 Ne7354dbb3d2c4ea68718600f6d530ccf
    14 Ne9c6757a17834280a15bf575fa7e3b21
    15 Nffe3d110a25d4f7382cf0604d4f2ccad
    16 anzsrc-for:06
    17 anzsrc-for:0601
    18 anzsrc-for:0604
    19 schema:author N6f7d2a9b026a4ecc9f2845de8b180244
    20 schema:citation sg:pub.10.1038/nature02871
    21 sg:pub.10.1038/nature03076
    22 sg:pub.10.1038/nature03121
    23 sg:pub.10.1038/nature03315
    24 sg:pub.10.1038/nature03552
    25 sg:pub.10.1038/nature03702
    26 sg:pub.10.1038/nature03817
    27 sg:pub.10.1038/ng1536
    28 sg:pub.10.1038/nrg1379
    29 sg:pub.10.1038/sj.gt.3302654
    30 schema:datePublished 2005-10-30
    31 schema:datePublishedReg 2005-10-30
    32 schema:description miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function — and a potential therapeutic strategy for silencing miRNAs in disease. These ‘antagomirs’ are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation.
    33 schema:genre article
    34 schema:isAccessibleForFree false
    35 schema:isPartOf N033a1712f44c462390051166afa30224
    36 N626b06a6d5184dd4bb5561dc70819e73
    37 sg:journal.1018957
    38 schema:keywords HOXB8
    39 RNA
    40 accurate expression
    41 acts
    42 administration
    43 adrenals
    44 antagomir
    45 biological processes
    46 bone marrow
    47 compounds
    48 developmental genes
    49 developmental processes
    50 developmental role
    51 discovery
    52 disease
    53 embryos
    54 example
    55 examples of miRNAs
    56 expression
    57 factors
    58 fat
    59 flies
    60 function
    61 gene regulation
    62 genes
    63 group
    64 group of compounds
    65 heart
    66 idea
    67 important developmental role
    68 intestine
    69 intravenous administration
    70 kidney
    71 levels
    72 liver
    73 lung
    74 mammalian systems
    75 marked reduction
    76 marrow
    77 mechanism
    78 miR-16
    79 miRNA expression
    80 miRNA regulation
    81 miRNAs
    82 mice
    83 microRNAs
    84 mouse embryos
    85 muscle
    86 natural miRNAs
    87 non-coding RNA
    88 oligonucleotide
    89 ovaries
    90 perception
    91 potential therapeutic strategy
    92 powerful tool
    93 process
    94 reduction
    95 regulation
    96 role
    97 secondary level
    98 sequence
    99 skin
    100 specific role
    101 strategies
    102 study
    103 such example
    104 system
    105 target
    106 therapeutic strategies
    107 tool
    108 transcription factors
    109 vertebrates
    110 vivo
    111 worms
    112 schema:name Silencing of microRNAs in vivo with ‘antagomirs’
    113 schema:pagination 685-689
    114 schema:productId Nd18debe8d692484d8c0baa083984de8f
    115 Ne390227010204c2ab83cdabea737a2eb
    116 Ne435e59720d44024b504849f7f40c41f
    117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045870087
    118 https://doi.org/10.1038/nature04303
    119 schema:sdDatePublished 2022-10-01T06:33
    120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    121 schema:sdPublisher Nde1a2b4819bb40fd9f3c222bd4b3eeb0
    122 schema:url https://doi.org/10.1038/nature04303
    123 sgo:license sg:explorer/license/
    124 sgo:sdDataset articles
    125 rdf:type schema:ScholarlyArticle
    126 N033a1712f44c462390051166afa30224 schema:issueNumber 7068
    127 rdf:type schema:PublicationIssue
    128 N0f49aa104252477485bf87ab180653d0 rdf:first sg:person.01211623670.71
    129 rdf:rest rdf:nil
    130 N18e178dc693841798b150d78fec22d57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name RNA, Complementary
    132 rdf:type schema:DefinedTerm
    133 N1edaad83b596466cba2b2ea6f90d23bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Oligonucleotides
    135 rdf:type schema:DefinedTerm
    136 N314d03769f814e8e9bb37a1f405b1cf6 rdf:first sg:person.0650611705.98
    137 rdf:rest N0f49aa104252477485bf87ab180653d0
    138 N4fdf5a633bfb45d39f82a8cb84ef1ba7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Antagomirs
    140 rdf:type schema:DefinedTerm
    141 N57cc4bd1697f45e3818fbee81d4a2d6a rdf:first sg:person.01127665173.29
    142 rdf:rest N6e19ca3a3ef640f2b2848ec9fbf4903a
    143 N619c8c5333ea4ffaa994d9a7ae09524f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Computational Biology
    145 rdf:type schema:DefinedTerm
    146 N626b06a6d5184dd4bb5561dc70819e73 schema:volumeNumber 438
    147 rdf:type schema:PublicationVolume
    148 N6e19ca3a3ef640f2b2848ec9fbf4903a rdf:first sg:person.010011672437.34
    149 rdf:rest N314d03769f814e8e9bb37a1f405b1cf6
    150 N6f7d2a9b026a4ecc9f2845de8b180244 rdf:first sg:person.01326501171.27
    151 rdf:rest Nee80a1b4d137499bb51cd8350bc1b32e
    152 N7661ea684af44c93b40f20747dc86b66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Cholesterol
    154 rdf:type schema:DefinedTerm
    155 N8ed30c5c576d471e8ce6487cdb3480d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Sensitivity and Specificity
    157 rdf:type schema:DefinedTerm
    158 N964706bfd5884740a88fc015521b91b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Mice
    160 rdf:type schema:DefinedTerm
    161 Na3570e3fdec443eaa8287ccd3d48db5c rdf:first sg:person.0651210271.51
    162 rdf:rest N57cc4bd1697f45e3818fbee81d4a2d6a
    163 Nb8ff85016fb9493785003831264faadf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Time Factors
    165 rdf:type schema:DefinedTerm
    166 Nb95ecda74ff74ebca32da74673d7db94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name 3' Untranslated Regions
    168 rdf:type schema:DefinedTerm
    169 Nc67b059184894c4f940ce6b793b2fbc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Down-Regulation
    171 rdf:type schema:DefinedTerm
    172 Nd18debe8d692484d8c0baa083984de8f schema:name pubmed_id
    173 schema:value 16258535
    174 rdf:type schema:PropertyValue
    175 Nd4f6df786a5e4d5d9f0ad854f980fa7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Animals
    177 rdf:type schema:DefinedTerm
    178 Nde1a2b4819bb40fd9f3c222bd4b3eeb0 schema:name Springer Nature - SN SciGraph project
    179 rdf:type schema:Organization
    180 Ne36d941fae9747f3b0d6ba6fe57b47aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Gene Silencing
    182 rdf:type schema:DefinedTerm
    183 Ne390227010204c2ab83cdabea737a2eb schema:name doi
    184 schema:value 10.1038/nature04303
    185 rdf:type schema:PropertyValue
    186 Ne435e59720d44024b504849f7f40c41f schema:name dimensions_id
    187 schema:value pub.1045870087
    188 rdf:type schema:PropertyValue
    189 Ne7354dbb3d2c4ea68718600f6d530ccf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Up-Regulation
    191 rdf:type schema:DefinedTerm
    192 Ne9c6757a17834280a15bf575fa7e3b21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Substrate Specificity
    194 rdf:type schema:DefinedTerm
    195 Nee80a1b4d137499bb51cd8350bc1b32e rdf:first sg:person.0604110653.10
    196 rdf:rest Na3570e3fdec443eaa8287ccd3d48db5c
    197 Nffe3d110a25d4f7382cf0604d4f2ccad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name MicroRNAs
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Biological Sciences
    202 rdf:type schema:DefinedTerm
    203 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Biochemistry and Cell Biology
    205 rdf:type schema:DefinedTerm
    206 anzsrc-for:0604 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Genetics
    208 rdf:type schema:DefinedTerm
    209 sg:journal.1018957 schema:issn 0028-0836
    210 1476-4687
    211 schema:name Nature
    212 schema:publisher Springer Nature
    213 rdf:type schema:Periodical
    214 sg:person.010011672437.34 schema:affiliation grid-institutes:grid.134907.8
    215 schema:familyName Tuschl
    216 schema:givenName Thomas
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010011672437.34
    218 rdf:type schema:Person
    219 sg:person.01127665173.29 schema:affiliation grid-institutes:grid.417897.4
    220 schema:familyName Rajeev
    221 schema:givenName Kallanthottathil G.
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127665173.29
    223 rdf:type schema:Person
    224 sg:person.01211623670.71 schema:affiliation grid-institutes:grid.134907.8
    225 schema:familyName Stoffel
    226 schema:givenName Markus
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211623670.71
    228 rdf:type schema:Person
    229 sg:person.01326501171.27 schema:affiliation grid-institutes:grid.134907.8
    230 schema:familyName Krützfeldt
    231 schema:givenName Jan
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326501171.27
    233 rdf:type schema:Person
    234 sg:person.0604110653.10 schema:affiliation grid-institutes:grid.137628.9
    235 schema:familyName Rajewsky
    236 schema:givenName Nikolaus
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604110653.10
    238 rdf:type schema:Person
    239 sg:person.0650611705.98 schema:affiliation grid-institutes:grid.417897.4
    240 schema:familyName Manoharan
    241 schema:givenName Muthiah
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650611705.98
    243 rdf:type schema:Person
    244 sg:person.0651210271.51 schema:affiliation grid-institutes:grid.417897.4
    245 schema:familyName Braich
    246 schema:givenName Ravi
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651210271.51
    248 rdf:type schema:Person
    249 sg:pub.10.1038/nature02871 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043341870
    250 https://doi.org/10.1038/nature02871
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/nature03076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050225907
    253 https://doi.org/10.1038/nature03076
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/nature03121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043296399
    256 https://doi.org/10.1038/nature03121
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/nature03315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002085290
    259 https://doi.org/10.1038/nature03315
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1038/nature03552 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020637207
    262 https://doi.org/10.1038/nature03552
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1038/nature03702 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024825726
    265 https://doi.org/10.1038/nature03702
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/nature03817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035771095
    268 https://doi.org/10.1038/nature03817
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/ng1536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037192337
    271 https://doi.org/10.1038/ng1536
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/nrg1379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001799892
    274 https://doi.org/10.1038/nrg1379
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/sj.gt.3302654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022653137
    277 https://doi.org/10.1038/sj.gt.3302654
    278 rdf:type schema:CreativeWork
    279 grid-institutes:grid.134907.8 schema:alternateName Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    280 Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    281 schema:name Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    282 Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    283 rdf:type schema:Organization
    284 grid-institutes:grid.137628.9 schema:alternateName Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA
    285 schema:name Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA
    286 rdf:type schema:Organization
    287 grid-institutes:grid.417897.4 schema:alternateName Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA
    288 schema:name Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA
    289 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...